Community Academic Profiles

David B. Lewis

Publication Details

  • Asymmetric dimethylarginine and cardiac allograft vasculopathy progression: modulation by sirolimus.

    Potena L, Fearon WF, Sydow K, Holweg C, Luikart H, Chin C, Weisshaar D, Mocarski ES, Lewis DB, Valantine HA, Cooke JP. Transplantation. 2008; 85 (6): 827-33

    Cardiac allograft vasculopathy (CAV) is a major cause of death after heart transplantation (HT). The reduced bioavailability of endothelium-derived nitric oxide may play a role in endothelial vasodilator dysfunction and thus in the structural changes characterizing CAV. A potential contributor to endothelial pathobiology is asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor. It was hypothesized that ADMA concentrations may influence CAV progression during the first postoperative year.

    PubMedID: 18360263

Stanford Medicine Resources:

Footer Links: